REGRESS Trial
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
REGRESS Trial On the Web |
|
American Roentgen Ray Society Images of REGRESS Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To evaluate the effects of cholesterol lowering therapy, using a hydroxymethyl glutaryl coenzyme A reductase inhibitor (pravastatin) in symptomatic men with coronary artery disease (CAD).
Methods
Regression Growth Evaluation Statin Study (REGRESS) was a multicentered, prospective, double-blinded, randomized, placebo-controlled trial that enrolled 885 men with established coronary artery disease with total cholesterol levels in the range of 155 and 310 mg/dL. The patients were randomized into two groups, treatment and control and followed up for two years. Effect of pravastatin on progression and regression of coronary atherosclerosis was assessed by quantitative coronary arteriography. All the patients received routine antianginal treatment for the duration of the trial.
Results
Percent diameter stenosis before angioplasty was 78 +/- 14% (mean +/- SD) in the pravastatin group and 80 +/- 14% in the placebo group (p = 0.46). At follow-up, the percent diameter stenosis was 32 +/- 23% in the pravastatin group and 45 +/- 29% in the placebo group (p < 0.001). Clinical restenosis was significantly lower in the pravastatin group (7%) compared with the placebo group (29%) (p < 0.001).
Conclusion
In symptomatic men with significant coronary artery disease and normal to moderately elevated serum cholesterol, less progression of coronary atherosclerosis and fewer new cardiovascular events were observed in the group of patients treated with pravastatin than in the placebo group.[1][2][3][4]
References
- ↑ Jukema JW, Bruschke AV, van Boven AJ; et al. (1995). "Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)". Circulation. 91 (10): 2528–40. PMID 7743614. Unknown parameter
|month=ignored (help) - ↑ van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV (1996). "Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group". Circulation. 94 (7): 1503–5. PMID 8840836. Unknown parameter
|month=ignored (help) - ↑ Mulder HJ, Bal ET, Jukema JW; et al. (2000). "Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial)". Am. J. Cardiol. 86 (7): 742–6. PMID 11018193. Unknown parameter
|month=ignored (help) - ↑ Barth JD, Zonjee MM (1992). "Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group". Can J Cardiol. 8 (9): 925–32. PMID 1486543. Unknown parameter
|month=ignored (help)